These results, together with previous studies on human brain tissues in the context of other pathologies, such as traumatic brain injury and multiple sclerosis [25, 49], led to the consideration of GPR17 as a promising pharmacological target to promote remyelination in ischaemic stroke. The gene discussed is GPR17; the disease is multiple sclerosis.